HRP20180216T1 - Fuzijski proteini i kombinacijska cjepiva koja sadrže protein e i pilin a iz bakterije haemophilus influenzae - Google Patents
Fuzijski proteini i kombinacijska cjepiva koja sadrže protein e i pilin a iz bakterije haemophilus influenzae Download PDFInfo
- Publication number
- HRP20180216T1 HRP20180216T1 HRP20180216TT HRP20180216T HRP20180216T1 HR P20180216 T1 HRP20180216 T1 HR P20180216T1 HR P20180216T T HRP20180216T T HR P20180216TT HR P20180216 T HRP20180216 T HR P20180216T HR P20180216 T1 HRP20180216 T1 HR P20180216T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- fusion protein
- protein according
- amino acids
- immunogenic
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title claims 23
- 108020001507 fusion proteins Proteins 0.000 title claims 23
- 241000606768 Haemophilus influenzae Species 0.000 title claims 6
- 229960005486 vaccine Drugs 0.000 title claims 5
- 102000004169 proteins and genes Human genes 0.000 title claims 3
- 108090000623 proteins and genes Proteins 0.000 title claims 3
- 108010000916 Fimbriae Proteins Proteins 0.000 title 1
- 229940047650 haemophilus influenzae Drugs 0.000 title 1
- 230000002163 immunogen Effects 0.000 claims 13
- 150000001413 amino acids Chemical class 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 241001377010 Pila Species 0.000 claims 4
- 101710204837 Envelope small membrane protein Proteins 0.000 claims 3
- 101710088839 Replication initiation protein Proteins 0.000 claims 3
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 230000009798 acute exacerbation Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 101150040383 pel2 gene Proteins 0.000 claims 2
- 101150050446 pelB gene Proteins 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 101710188053 Protein D Proteins 0.000 claims 1
- 101710132893 Resolvase Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (24)
1. Fuzijski protein formule I:
(X)m-(R1)n-A-(Y)o-B-(Z)- (formula I)
naznačen time što:
X je signalni peptid ili MHHHHHH (SEQ ID NO. 2);
m je 0 ili 1;
R1 je aminokiselina;
n je 0, 1, 2, 3, 4, 5 ili 6;
A je imunogeni fragment Proteina E koji se bira između SEQ ID NO. 122, SEQ ID NO. 123, SEQ ID NO. 124, SEQ ID NO. 125, SEQ ID NO. 126, SEQ ID NO. 179 ili SEQ ID NO. 180 ili slijed koji je najmanje 95% istovjetan bilo kojem od sljedova SEQ ID NO. 122, SEQ ID NO. 123, SEQ ID NO. 124, SEQ ID NO. 125, SEQ ID NO. 126, SEQ ID NO. 179 ili SEQ ID NO.180;
Y se bira iz skupine koju čine GG, SG, SS, GGG i (G)h, gdje je h 4, 5, 6, 7, 8, 9 ili 10;
o je 0 ili 1;
B je imunogeni fragment PilA, najmanje 95% istovjetan aminokiselinama 40-149 iz bilo kojeg od SEQ ID NO. 58 do SEQ ID NO. 121;
Z je GGHHHHHH (SEQ ID NO. 3); i
p je 0 ili 1.
2. Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što je X signalni peptid iz proteina koji se bira iz skupine koju čine Flgl, NadA i pelB.
3. Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što je m 0.
4. Fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što je A imunogeni fragment Proteina E iz bakterije H. influenzae, koji se bira iz skupine koju čine aminokiseline 17-160 iz SEQ ID NO. 4 (SEQ ID NO. 122), aminokiseline 18-160 iz SEQ ID NO. 4 (SEQ ID NO. 123), aminokiseline 19-160 iz SEQ ID NO. 4 (SEQ ID NO. 124), aminokiseline 20-160 iz SEQ ID NO. 4 (SEQ ID NO. 125), aminokiseline 22-160 iz SEQ ID NO. 4 (SEQ ID NO. 126), aminokiseline 23-160 iz SEQ ID NO. 4 (SEQ ID NO. 179) i aminokiseline 24-160 iz SEQ ID NO. 4 (SEQ ID NO. 180).
5. Fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je B imunogeni fragment PilA koju čine aminokiseline 40-149 iz bilo kojeg od SEQ ID NO. 58-SEQ ID NO. 121.
6. Fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je B imunogeni fragment PilA iz bakterije H. influenzae, kao što je iznijeto u SEQ ID NO. 127.
7. Fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što je A SEQ ID NO. 125.
8. Fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što je A SEQ ID NO. 124.
9. Fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je B fragment PilA, kao što je iznijeto u SEQ ID NO. 127, a A je imunogeni fragment Proteina E, koji se bira iz skupine koju čine SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 125 i SEQ ID NO. 126.
10. Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što se bira iz skupine koju čine SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202 ili SEQ ID NO. 204.
11. Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što se bira iz skupine koju čine SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202 ili SEQ ID NO. 204, gdje je signalni peptid uklonjen.
12. Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što ima SEQ ID NO. 148.
13. Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što ima SEQ ID NO. 177 (QIQKAEQN DVKLAPPTDV RSGYIRLVKN VNYYIDSESI WVDNQEPQIV HFDAVVNLDK GLYVYPEPKR YARSVRQYKI LNCANYHLTQ VRTDFYDEFW GQGLRAAPKK QKKHTLSLTP DTTLYNAAQI ICANYGEAFS VDKKGGTKKA AVSELLQASA PYKADVELCV YSTNETTNCT GGKNGIAADI TTAKGYVKSV TTSNGAITVK GDGTLANMEY ILQATGNAAT GVTWTTTCKG TDASLFPANF CGSVTQ).
14. Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što ima SEQ ID NO. 194.
15. Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što ima SEQ ID NO. 219 (IQKAEQND VKLAPPTDVR SGYIRLVKNV NYYIDSESIW VDNQEPQIVH FDAVVNLDKG LYVYPEPKRY ARSVRQYKIL NCANYHLTQV RTDFYDEFWG QGLRAAPKKQ KKHTLSLTPD TTLYNAAQII CANYGEAFSV DKKGGTKKAA VSELLQASAP YKADVELCVY STNETTNCTG GKNGIAADIT TAKGYVKSVT TSNGAITVKG DGTLANMEYI LQATGNAATG VTWTTTCKGT DASLFPANFC GSVTQ).
16. Imunogeni pripravak, naznačen time što sadrži fuzijski proteini u skladu s bilo kojim od patentnih zahtjeva 1-15.
17. Imunogeni pripravak u skladu s patentnim zahtjevom 16, naznačen time što dodatno sadrži Protein D iz bakterije H. influenzae.
18. Imunogeni pripravak u skladu s patentnim zahtjevom 16 ili patentnim zahtjevom 17, naznačen time što dodatno sadrži adjuvans, gdje adjuvans može biti AS01, primjerice AS01B ili AS01E.
19. Cjepivo, naznačeno time što sadrži fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1-15 ili imunogeni pripravak u skladu s patentnim zahtjevima 16-18.
20. Fuzijski protein u skladu s patentnim zahtjevima 1-15, ili imunogeni pripravak u skladu s patentnim zahtjevima 16-18, ili cjepivo u skladu s patentnim zahtjevom 19, naznačeni time što su namijenjeni upotrebi u liječenju ili sprječavanju upale srednjeg uha.
21. Fuzijski protein, imunogeni pripravak, ili cjepivo u skladu s patentnim zahtjevima 1-19, naznačeni time što su
– namijenjeni upotrebi u liječenju ili sprječavanju akutnih egzacerbacija kronične opstruktivne plućne bolesti (AE-COPD); i/ili
– namijenjeni upotrebi u liječenju ili sprječavanju pneumonije; i/ili
– namijenjeni upotrebi u liječenju ili sprječavanju infekcije ili bolesti koje uzrokuje bakterija H. influenzae.
22. Fuzijski protein, imunogeni pripravak, ili cjepivo u skladu s patentnim zahtjevima 1-19, naznačeni time što su namijenjeni upotrebi u liječenju ili sprječavanju akutnih egzacerbacija kronične opstruktivne plućne bolesti (AE-COPD).
23. Fuzijski protein u skladu s patentnim zahtjevima 1-15, naznačen time što je namijenjen upotrebi u poticanju imunosnog odgovora protiv bakterije H. influenzae kod ljudi.
24. Postupak postizanja periplazmtske ekspresije fuzijskog proteina u skladu s patentnim zahtjevima 1-15, naznačen time što se postupak sastoji u poticanju ekspresije proteina koji sadrže signalni peptid, gdje se signalni peptid bira između Flgl ili pelB.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474779P | 2011-04-13 | 2011-04-13 | |
| US201161534012P | 2011-09-13 | 2011-09-13 | |
| PCT/CA2012/050236 WO2012139225A1 (en) | 2011-04-13 | 2012-04-12 | Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a |
| EP12771540.7A EP2707393B1 (en) | 2011-04-13 | 2012-04-12 | Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180216T1 true HRP20180216T1 (hr) | 2018-03-09 |
Family
ID=47008755
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180216TT HRP20180216T1 (hr) | 2011-04-13 | 2018-02-06 | Fuzijski proteini i kombinacijska cjepiva koja sadrže protein e i pilin a iz bakterije haemophilus influenzae |
| HRP20200466TT HRP20200466T1 (hr) | 2011-04-13 | 2020-03-20 | Fuzijski proteini i kombinacijska cjepiva |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200466TT HRP20200466T1 (hr) | 2011-04-13 | 2020-03-20 | Fuzijski proteini i kombinacijska cjepiva |
Country Status (34)
| Country | Link |
|---|---|
| US (7) | US8945577B2 (hr) |
| EP (2) | EP2707393B1 (hr) |
| JP (1) | JP6196963B2 (hr) |
| KR (1) | KR101999673B1 (hr) |
| CN (3) | CN103476799A (hr) |
| AR (1) | AR086078A1 (hr) |
| AU (1) | AU2012243412C1 (hr) |
| BR (1) | BR112013026175B1 (hr) |
| CA (1) | CA2830786C (hr) |
| CL (1) | CL2013002937A1 (hr) |
| CO (1) | CO6781540A2 (hr) |
| CR (1) | CR20130529A (hr) |
| CY (2) | CY1120319T1 (hr) |
| DK (2) | DK3321287T3 (hr) |
| DO (1) | DOP2013000235A (hr) |
| EA (1) | EA031580B1 (hr) |
| ES (2) | ES2658512T3 (hr) |
| HR (2) | HRP20180216T1 (hr) |
| HU (2) | HUE036983T2 (hr) |
| IL (2) | IL271862B (hr) |
| LT (2) | LT3321287T (hr) |
| MA (1) | MA35110B1 (hr) |
| ME (1) | ME02995B (hr) |
| MX (1) | MX350013B (hr) |
| PE (1) | PE20140986A1 (hr) |
| PL (2) | PL2707393T3 (hr) |
| PT (2) | PT3321287T (hr) |
| RS (1) | RS56903B1 (hr) |
| SG (2) | SG193906A1 (hr) |
| SI (2) | SI2707393T1 (hr) |
| TW (1) | TW201302779A (hr) |
| UY (1) | UY34017A (hr) |
| WO (1) | WO2012139225A1 (hr) |
| ZA (1) | ZA201307118B (hr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
| GB201218660D0 (en) | 2012-10-17 | 2012-11-28 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| EP2908854A2 (en) * | 2012-10-17 | 2015-08-26 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| CN107072239A (zh) | 2013-09-30 | 2017-08-18 | 岛修道院食品有限公司 | 可咀嚼产品和用于制备其的方法 |
| TW201620927A (zh) | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | Ｕｓｐａ２蛋白質構築體及其用途 |
| US10648966B2 (en) * | 2015-01-16 | 2020-05-12 | University Of Kentucky Research Foundation | Lipid bilayer-integrated SPP1 connector protein nanopore and SPP1 connector protein variants for use as lipid bilayer-integrated nanopore |
| CN105175549B (zh) * | 2015-09-30 | 2019-08-16 | 康希诺生物股份公司 | 一种流感嗜血杆菌融合蛋白及其构建方法与应用 |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| WO2018178265A1 (en) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
| BR112019020209A2 (pt) * | 2017-03-31 | 2020-06-02 | Glaxosmithkline Intellectual Property Development Limited | Composição imunogênica, uso de uma composição imunogênica, método de tratamento ou prevenção de uma recorrência de uma exacerbação aguda de doença pulmonar obstrutiva crônica, e, terapia de combinação. |
| JP7291633B2 (ja) | 2017-05-30 | 2023-06-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アジュバントを製造する方法 |
| BR112020001768A2 (pt) | 2017-08-14 | 2020-09-29 | Glaxosmithkline Biologicals S.A. | método de reforçar uma resposta imune pré-existente contra haemophilus influenzae e moraxella catarrhalis não tipáveis em um indivíduo, e, protocolo de vacinação. |
| CN107602697B (zh) * | 2017-08-29 | 2020-05-05 | 杭州医学院 | 一种治疗流感嗜血杆菌引起鼻窦炎的血清及该血清的应用 |
| CA3083078A1 (en) | 2017-12-01 | 2019-06-06 | Glaxosmithkline Biologicals Sa | Saponin purification |
| CN112703006A (zh) * | 2018-06-19 | 2021-04-23 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| MX2021001479A (es) | 2018-08-07 | 2021-04-28 | Glaxosmithkline Biologicals Sa | Novedosos procesos y vacunas. |
| US20220339282A1 (en) | 2018-11-29 | 2022-10-27 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
| CN110540597B (zh) * | 2018-12-20 | 2021-04-30 | 湖北工业大学 | 基于流感嗜血杆菌表面蛋白的乳胶微球免疫层析试纸的制备方法 |
| CN110540598B (zh) * | 2018-12-20 | 2021-04-30 | 湖北工业大学 | 基于流感嗜血杆菌表面蛋白抗体的流感嗜血杆菌Elisa检测试剂盒及制备方法 |
| US20220143168A1 (en) | 2019-02-27 | 2022-05-12 | Evaxion Biotech A/S | Vaccines targeting H. influenzae |
| US20220221455A1 (en) | 2019-04-18 | 2022-07-14 | Glaxosmithkline Biologicals Sa | Antigen binding proteins and assays |
| US20220235095A1 (en) | 2019-06-05 | 2022-07-28 | Glaxosmithkline Biologicals Sa | Saponin purification |
| CA3148928A1 (en) * | 2019-08-05 | 2021-02-11 | Glaxosmithkline Biologicals Sa | Process for preparing a composition comprising a protein d polypeptide |
| WO2021023691A1 (en) | 2019-08-05 | 2021-02-11 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| JP2024510717A (ja) | 2021-02-22 | 2024-03-11 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物、使用及び方法 |
| KR20220142219A (ko) * | 2021-04-14 | 2022-10-21 | 한국생명공학연구원 | 장내 미생물에서 단백질 분비를 유도하는 신호서열 |
| WO2024017827A1 (en) | 2022-07-19 | 2024-01-25 | Glaxosmithkline Biologicals Sa | Continuous process for vaccine production |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE454403B (sv) | 1984-05-30 | 1988-05-02 | Alfa Laval Agri Int | Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| KR100188323B1 (ko) | 1989-03-09 | 1999-06-01 | 이곤 이이 버어그 | 비타입성 헤모필루스 인플렌자에 대한 백신 |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| ES2143716T3 (es) | 1992-06-25 | 2000-05-16 | Smithkline Beecham Biolog | Composicion de vacuna que contiene adyuvantes. |
| SG48309A1 (en) | 1993-03-23 | 1998-04-17 | Smithkline Beecham Biolog | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| EP1167377B2 (en) | 1994-07-15 | 2012-08-08 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
| SK176197A3 (en) | 1995-06-23 | 1998-07-08 | Smithkline Beecham Biolog | A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
| EP0948625B1 (en) | 1996-12-20 | 2011-01-26 | The Board Of Regents, The University Of Texas System | Uspa1 and uspa2 antigens of moraxella catarrhalis |
| ES2298269T3 (es) | 2000-09-26 | 2008-05-16 | Idera Pharmaceuticals, Inc. | Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales. |
| DK2270171T5 (da) | 2000-10-02 | 2013-11-18 | Id Biomedical Corp Quebec | Haemophilus influenzae-antigener og tilsvarende DNA-fragmenter |
| US6942802B2 (en) | 2001-04-13 | 2005-09-13 | Wyeth Holdings Corporation | Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| GB0222764D0 (en) | 2002-10-02 | 2002-11-06 | Univ Bristol | Therapeutic peptide |
| CN1894581B (zh) | 2003-07-09 | 2012-02-01 | 生命技术公司 | 检测蛋白-蛋白相互作用的方法 |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| WO2006119983A2 (en) * | 2005-05-12 | 2006-11-16 | Novartis Ag | Genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy |
| JP5042218B2 (ja) * | 2005-07-08 | 2012-10-03 | ユニバーシティ・オブ・チューリッヒ | 融合ポリペプチドの翻訳と同時のトランスロケーションを使用するファージディスプレイ |
| WO2007008527A2 (en) | 2005-07-08 | 2007-01-18 | Children's Hospital Inc. | Chimeric vaccine for haemophilus influenzae-induced disease |
| AU2006277076B2 (en) | 2005-08-10 | 2012-03-29 | Arne Forsgren Ab | Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system |
| ZA200805602B (en) * | 2006-01-17 | 2009-12-30 | Arne Forsgren | A novel surface exposed haemophilus influenzae protein (protein E; pE) |
| GB2444903A (en) * | 2006-12-21 | 2008-06-25 | Secr Defence | Live Francisella vaccine, inactivated at gene FTT1564 |
| WO2009154025A1 (ja) | 2008-06-20 | 2009-12-23 | 国立大学法人岡山大学 | 酸化LDL/β2GPI複合体に対する抗体及びその用途 |
| TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
-
2012
- 2012-04-11 TW TW101112896A patent/TW201302779A/zh unknown
- 2012-04-12 EP EP12771540.7A patent/EP2707393B1/en active Active
- 2012-04-12 BR BR112013026175-7A patent/BR112013026175B1/pt active IP Right Grant
- 2012-04-12 SI SI201231223T patent/SI2707393T1/en unknown
- 2012-04-12 PL PL12771540T patent/PL2707393T3/pl unknown
- 2012-04-12 EP EP17201766.7A patent/EP3321287B1/en active Active
- 2012-04-12 ME MEP-2018-15A patent/ME02995B/me unknown
- 2012-04-12 MX MX2013011939A patent/MX350013B/es active IP Right Grant
- 2012-04-12 US US14/110,857 patent/US8945577B2/en active Active
- 2012-04-12 RS RS20180176A patent/RS56903B1/sr unknown
- 2012-04-12 HU HUE12771540A patent/HUE036983T2/hu unknown
- 2012-04-12 LT LTEP17201766.7T patent/LT3321287T/lt unknown
- 2012-04-12 CN CN2012800180323A patent/CN103476799A/zh active Pending
- 2012-04-12 PE PE2013002281A patent/PE20140986A1/es not_active Application Discontinuation
- 2012-04-12 CA CA2830786A patent/CA2830786C/en active Active
- 2012-04-12 CN CN201710655782.6A patent/CN107383201A/zh active Pending
- 2012-04-12 DK DK17201766.7T patent/DK3321287T3/da active
- 2012-04-12 PT PT172017667T patent/PT3321287T/pt unknown
- 2012-04-12 DK DK12771540.7T patent/DK2707393T3/da active
- 2012-04-12 EA EA201391240A patent/EA031580B1/ru not_active IP Right Cessation
- 2012-04-12 SI SI201231775T patent/SI3321287T1/sl unknown
- 2012-04-12 HU HUE17201766A patent/HUE048848T2/hu unknown
- 2012-04-12 AR ARP120101264A patent/AR086078A1/es active IP Right Grant
- 2012-04-12 WO PCT/CA2012/050236 patent/WO2012139225A1/en active Application Filing
- 2012-04-12 AU AU2012243412A patent/AU2012243412C1/en active Active
- 2012-04-12 CN CN201710656150.1A patent/CN107522788A/zh active Pending
- 2012-04-12 ES ES12771540.7T patent/ES2658512T3/es active Active
- 2012-04-12 KR KR1020137029993A patent/KR101999673B1/ko active IP Right Grant
- 2012-04-12 PT PT127715407T patent/PT2707393T/pt unknown
- 2012-04-12 SG SG2013068663A patent/SG193906A1/en unknown
- 2012-04-12 IL IL271862A patent/IL271862B/en unknown
- 2012-04-12 JP JP2014504132A patent/JP6196963B2/ja active Active
- 2012-04-12 LT LTEP12771540.7T patent/LT2707393T/lt unknown
- 2012-04-12 SG SG10201602549WA patent/SG10201602549WA/en unknown
- 2012-04-12 UY UY0001034017A patent/UY34017A/es not_active Application Discontinuation
- 2012-04-12 PL PL17201766T patent/PL3321287T3/pl unknown
- 2012-04-12 ES ES17201766T patent/ES2776369T3/es active Active
-
2013
- 2013-09-11 IL IL228344A patent/IL228344B/en active IP Right Grant
- 2013-09-20 ZA ZA2013/07118A patent/ZA201307118B/en unknown
- 2013-10-09 CO CO13240514A patent/CO6781540A2/es unknown
- 2013-10-10 DO DO2013000235A patent/DOP2013000235A/es unknown
- 2013-10-11 CL CL2013002937A patent/CL2013002937A1/es unknown
- 2013-10-14 CR CR20130529A patent/CR20130529A/es unknown
- 2013-11-08 MA MA36409A patent/MA35110B1/fr unknown
-
2014
- 2014-12-16 US US14/571,546 patent/US9296794B2/en active Active
- 2014-12-16 US US14/571,807 patent/US9409957B2/en active Active
-
2016
- 2016-02-18 US US15/046,908 patent/US10023616B2/en active Active
- 2016-06-30 US US15/197,952 patent/US10214569B2/en active Active
-
2018
- 2018-01-04 US US15/861,789 patent/US10730917B2/en active Active
- 2018-02-06 HR HRP20180216TT patent/HRP20180216T1/hr unknown
- 2018-02-28 CY CY20181100257T patent/CY1120319T1/el unknown
-
2020
- 2020-03-13 CY CY20201100222T patent/CY1122824T1/el unknown
- 2020-03-20 HR HRP20200466TT patent/HRP20200466T1/hr unknown
- 2020-07-07 US US16/922,112 patent/US11198707B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180216T1 (hr) | Fuzijski proteini i kombinacijska cjepiva koja sadrže protein e i pilin a iz bakterije haemophilus influenzae | |
| HRP20181102T1 (hr) | Cjepiva za hsv-2 | |
| HRP20211926T1 (hr) | Konstrukti proteina uspa2 i njihova upotreba | |
| WO2018109220A3 (en) | Novel recombinant prefusion rsv f proteins and uses thereof | |
| JP2017507181A5 (hr) | ||
| HRP20170094T1 (hr) | Imunogeni pripravak | |
| HRP20180064T1 (hr) | Cjepiva s kapsularnim biokonjugatima iz gram-pozitivnih bakterija | |
| WO2014160463A8 (en) | Prefusion rsv f proteins and their use | |
| HRP20191166T1 (hr) | Stabilizirani proteini, namijenjeni imuniziranju protiv bakterije staphylococcus aureus | |
| JP2011250797A5 (hr) | ||
| WO2015024668A3 (en) | Respiratory syncytial virus (rsv) vaccine | |
| JP2016514713A5 (hr) | ||
| JP2015214545A5 (hr) | ||
| Hamod et al. | Outer membrane protein K as a subunit vaccine against V. anguillarum | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| HRP20240042T1 (hr) | Pripravci koji se odnose na mutantni toksin iz bakterije clostridium difficile i odgovarajući postupci | |
| JP2010166916A5 (hr) | ||
| RU2018116601A (ru) | Иммунногенный слитый белок | |
| JP2015533791A5 (hr) | ||
| HRP20191864T1 (hr) | Imunogeni pripravci protiv bakterije clostridium difficile | |
| JP2015529677A5 (hr) | ||
| WO2012174455A3 (en) | Group a streptococcus multivalent vaccine | |
| NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same | |
| JP2013542942A5 (hr) | ||
| JP2009527510A5 (hr) |